Kestra Medical’s Growth Hides Widening Losses

Forward-Looking Analysis

Analysts project Kestra Medical (KMTS) will report Q1 2027 revenue of $29.01 million, a significant increase from the $19.37 million recorded in the year-ago period. However, profitability remains a concern, with earnings per share (EPS) expected to be -$0.62, widening from the -$0.36 loss reported last year. Full-year 2027 revenue is estimated at $137.02 million, up from earlier estimates of $132.90 million, while full-year EPS is forecast at -$2.30, down from -$2.16. Despite the projected losses, analyst sentiment remains predominantly positive. The average one-year price target is $30.00, implying 27.33% upside from the current price of $23.56. Six analysts provide price targets ranging from $28.00 to $32.00. BTIG’s Marie Thibault maintains a Buy rating with a $32 target, while J.P. Morgan’s Robbie Marcus initiated an Overweight rating with a $30 target. Goldman Sachs’ David Roman maintains a Neutral rating but recently cut his target to $17. The consensus brokerage recommendation is 1.60, indicating an "Outperform" status.

Historical Performance Review

In the previous quarter ending April 30, 2026, Kestra Medical reported revenue of $28.64 million, beating analyst expectations of $26.48 million by 8.15%. Gross profit stood at $15.68 million, while net income was -$38.84 million. Earnings per share came in at -$0.67, missing the consensus estimate of -$0.59 by 13.18%. Following the report, shares rose 1.80% in one-day trading, suggesting market resilience despite the earnings miss.

Additional News

Kestra Medical has seen mixed analyst coverage and leadership changes recently. On September 10, the company appointed Daniel Finney as Vice President of Research & Development. Stock performance has been mixed; shares declined 2.1% to close at $23.57 on Thursday, September 12. Over the trailing twelve months ending September 11, 2026, KMTS delivered a total return of 24.18%, outperforming the S&P 500’s 16.24% return. Year-to-date returns stood at 13.84% compared to the S&P 500’s 11.85%. However, three-year and five-year returns lagged significantly behind the benchmark, recording 0.44% versus 70.63% and 71.74%, respectively. Additionally, insider activity has been noted, with director Kevin Reilly selling shares valued at $73,677, and another insider transaction involving $97,942 in stock sales for tax purposes.

Summary & Outlook

Kestra Medical demonstrates strong top-line growth, with Q1 revenue estimates rising sharply year-over-year. However, the company faces headwinds from widening net losses and negative EPS, raising concerns about short-term profitability. Growth catalysts include new R&D leadership and consistent analyst upgrades, though insider selling and widening losses present risks. While the "Outperform" consensus and upside potential in price targets suggest cautious optimism, the trajectory toward profitability remains unclear. The outlook is neutral-to-bearish in the near term due to loss expansion, but long-term prospects depend on sustaining revenue momentum while controlling costs.